flashContent
Company news

10 September 2020

Company Alkor Bio received registration certificate of Federal Service for Surveillance in Healthcare for the SARS-CoV-2EIA-IgG

On September 3, 2020 Company Alkor Bio received registration certificate of Federal Service for Surveillance in Healthcare for the SARS-CoV-2EIA-Ig.

SARS-CoV-2 EIA-IgG is intended for qualitative and semi-quantitative enzyme immunoassay for the determination of class G immunoglobulins to the SARS-CoV-2 virus. Semi-quantitative assessment of the level of IgG antibodies is achieved by titration.

SARS-CoV-2EIA-IgG has a sensitivity power of 100% and a specificity of 100%, which eliminates false positives.

An important feature of the SARS-CoV-2EIA-IgG test from Alkor Bio - there is no preliminary dilution of patient sera, which reduces the analysis time.

Two-stage test, the duration of the main incubations of the test is 1 hour (20 min + 40 min).

The indication of the addition is clearly visible - the buffer color changes from light green to blue, which makes it possible to exclude the omission of the addition of serum. All reagents in the kit are ready for use.